Rapid Therapeutic Science Laboratories
(OTC) RTSL
Rapid Therapeutic Science Laboratories Financials at a Glance
Market Cap
$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
$634.51K
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
-2.24 (Low)
Dividend
$0.00
Beta (Volatility)
-2.24 (Low)
Price
$0.00
Volume
442
Open
$0.00
Price
$0.00
Volume
442
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.01
Estimated Earnings Date
Mar 31, 2023
Dividend
$0.00
Beta (Volatility)
-2.24 (Low)
Price
$0.00
Volume
442
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.01
Estimated Earnings Date
Mar 31, 2023
RTSL News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Rapid Therapeutic Science Laboratories
Industry
Healthcare Equipment and Supplies
Sector
Health CareEmployees
2
CEO
Donal R. Schmidt, Jr., MBA
Headquarters
Dallas, TX 75201, US
RTSL Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
5.89%
Return on Capital
-22.97%
Return on Assets
-18.94%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
8.83M
Volume
442
Avg. Volume
36.484
Financials (TTM)
Gross Profit
-$5.99K
Operating Income
-$101.54K
EBITDA
-$98.83K
Operating Cash Flow
-$566.60K
Capital Expenditure
-$249.58K
Free Cash Flow
-$816.19K
Cash & ST Invst.
$0.00
Total Debt
$3.45M
Rapid Therapeutic Science Laboratories Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$5.99K
N/A
Gross Margin
0.00%
N/A
Market Cap
$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$300.00
N/A
Employees
3
N/A
Net Income
-$34.54K
+94.0%
EBITDA
-$3.39K
+99.0%
Quarterly Fundamentals
Total Cash
$0.00
N/A
Total Debt
$3.45M
-8.9%
Accounts Receivable
$0.00
N/A
Inventory
$175.05K
+0.0%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$3.45M
+4.0%
Return on Assets
-18.94%
N/A
Return on Invested Capital
2.70%
N/A
Free Cash Flow
-$7.33K
+97.1%
Operating Cash Flow
-$7.33K
+97.1%